Company intelligence
Biomea Fusion
Biomea’s mission is to deliver transformative treatments that restore health for patients living with metabolic diseases
About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure!
Verified activity
Signals from Biomea Fusion
6 published signals
Presence & Recognition
Biomea Fusion is looking forward to participating in Citi’s 2026 Biopharma Back to School Conference on Thursday, September 10, 2026, in New York, NY.
Reported by Biomea Fusion
Presence & Recognition
Biomea Fusion celebrated Labor Day by honoring the dedication and contributions of Team Fusion workers.
Reported by Biomea Fusion
Research & Knowledge
Biomea Fusion is developing ico, a potential first-in-class oral therapy designed to address a root cause of diabetes by restoring and preserving the body’s own insulin-producing beta cells.
Reported by Biomea Fusion
Presence & Recognition
Biomea Fusion is looking forward to participating in the Citi 2026 Biopharma Back to School Conference on Thursday, September 10, and the H.C. Wainwright & Co., LLC 28th Annual Global Investment Conference on Tuesday, September 15.
Reported by Biomea Fusion
Research & Knowledge
Biomea Fusion announced the first patient dosed in the OPAL Study, led by the University of Leicester, evaluating icovamenib in combination with low-dose semaglutide in obesity.
Reported by Biomea Fusion
People
Biomea Fusion appointed Mick Hitchcock as Interim CEO and a member of the Board of Directors.
Reported by Biomea Fusion